Search Results
Sep 08, 2026, 18:04 ET DISA's 9th Annual HR Screening, Safety, & Strategy Conference Returns to Houston January 14, 2027
environment.Attendees include professionals working across a variety of teams:Human resourcesWorkplace safetyDrug and alcohol testingBackground screeningTransportation complianceEmployment lawOccupational healthRisk and
More news about: DISA Global Solutions
Sep 08, 2026, 16:05 ET Tyra Biosciences to Present at the Cantor Global Healthcare Conference
next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and
More news about: Tyra Biosciences
Sep 08, 2026, 15:58 ET UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc.
alleges that Unicycive failed to properly inspect its third-party vendor's manufacturing facility to ensure it resolved the U.S. Food and Drug Administration's ("FDA") previously noted deficiencies.Investors who suffered significant losses during the Class Period may be eligible to participate
More news about: Robbins LLP
Sep 08, 2026, 15:16 ET UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the U.S. Food and Drug Administration's ("FDA") cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's
More news about: THE ROSEN LAW FIRM, P. A.
Sep 08, 2026, 14:34 ET FDA Advisory Panel Backs BPC-157 for 503A Bulks List in 8-6-1 Vote, Promise Analysis Finds
FDA's BPC-157 briefing document also states that neither form has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. Inclusion on a compounding bulks list, if ultimately completed through rulemaking, would still not make a compounded
More news about: Promise (mypromise.com)
Sep 08, 2026, 14:04 ET City of North Charleston Raises Awareness of 7-OH Risks as Federal Scrutiny Increases
gummies, powders, drink mixes, shots and dissolvable strips.Federal health officials are increasingly sounding the alarm.The U.S. Food and Drug Administration describes concentrated 7-OH products as potent opioid products that have not been proven safe or effective for any use. The FDA
More news about: City of North Charleston
Sep 08, 2026, 14:00 ET USPS To Issue Fentanyl Awareness Semipostal Stamp
Dr. Nora Volkow, National Institute on Drug Abuse director
More news about: U.S. Postal Service
Sep 08, 2026, 13:38 ET A Journey into the Unconscious: New Book Offers an Approachable Introduction to Carl Jung
interest in Jungian psychology, eastern spirituality, and the natural world. Her career has included working at the Hollywood YMCA with at-risk teenagers, drug and alcohol rehabilitation counseling, and many years of private practice with adolescents, adults, and families. She splits her time between Oldenburg,
More news about: Archway Publishing
Sep 08, 2026, 12:16 ET AFT Pharmaceuticals partners with Mark Cuban Cost Plus Marketplace to bring the new non-opioid pain medication, Combogesic® to the U.S.
epidermal necrolysis (TEN), or fixed drug eruption (FDE), generalized bullous fixed drug eruption (GBFDE), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® at the first appearance of skin rash or any other sign of hypersensitivity.Drug Rash with Eosinophilia and Systemic
More news about: AFT Pharmaceuticals
Sep 08, 2026, 10:58 ET Clinical Science Update | New Clinical Evidence for ClotChek™
Xa (FXa) inhibitors apixaban and rivaroxaban, demonstrating DOAC-sensitivity and strong correlations between the CKCT and the DOAC related anti-FXa drug levels when patients were categorized based on meaningful Medical Decision Limits (MDL), as well as the ability to detect clinically meaningful anticoagulation
More news about: Perosphere Technologies Inc.
Sep 08, 2026, 10:31 ET Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
outcomes.The US FDA has granted Orphan Drug Designation (ODD) to efzofitimod for the treatment of sarcoidosis, along with Fast Track Designation (FTD) for pulmonary sarcoidosis. In Europe, the European Commission has awarded efzofitimod Orphan Drug Designation for sarcoidosis following
More news about: DelveInsight Business Research, LLP
Sep 08, 2026, 10:30 ET Medical Supplies Market worth $248.03 billion by 2031 - Exclusive Report by MarketsandMarkets™
Disposable Medical Device Market by Device (Drug Delivery Devices, Surgical & Procedural Instruments, Personal Protective Equipment, Catheters & Tubes), Device Class (I, II, III), Material
More news about: MarketsandMarkets
Sep 08, 2026, 10:19 ET Pharmaceutical CDMO Market to Reach US$ 270.3 Bn by 2031, Growing at 7.2% CAGR, New Report by Wissen Research
timelines for both small-molecule and biopharmaceutical products. At the same time, rising demand for complex drug classes — including biologics, cell and gene therapies, antibody-drug conjugates (ADCs), and mRNA-based medicines — is pushing CDMOs to build out increasingly specialized manufacturing
More news about: Wissen Research LLC
Sep 08, 2026, 10:15 ET Laboratory Mixers Market worth $2.74 billion by 2031 - Exclusive Report by MarketsandMarkets™
& biotechnology companies segment is projected to witness the fastest growth during the forecast period. There has been increased drug-discovery and R&D activity. Drug formulation, analytical development, stability testing, dissolution work, assay preparation, and sample preparation require repeatable
More news about: MarketsandMarkets
Sep 08, 2026, 09:36 ET LivmorIQ Brings Real Medicare Beneficiary Data to Plan Analysis, The Year-Round Client Retention Platform for Agents and Agencies
as soon as it appears in the data. Through Livmor's monthly provider and formulary updates, it flags when a client's doctor leaves the network or a drug loses coverage or moves tiers, in time to reach the client before the Annual Notice of Change arrives at the end of September, not after.Leah
More news about: Livmor Inc.
Sep 08, 2026, 09:15 ET GS1 Connect 2027 Call for Presentations Now Open
chain. Topics may include:U.S. FDA Food Safety Modernization Act Traceability Rule (FSMA Rule 204), Drug Supply Chain Security Act (DSCSA), National Drug Code (NDC) format changes, Extended Producer Responsibility (EPR) and regulatory readinessRecall preparedness, track-and-trace
More news about: GS1 US
Sep 08, 2026, 09:05 ET Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp
Sep 08, 2026, 09:00 ET Global Genes Partners with Citizen Health to Power RARE-X
Global Genes' RARE Drug Development Symposium in Boston.
More news about: Global Genes
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients."Following the U.S. Food and Drug Administration (FDA) approval of IMDELLTRA for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy, the robust
More news about: Amgen
Sep 08, 2026, 08:48 ET AllyGPO Named to Fast Company's 2026 List of Best Workplaces for Innovators
purpose-built to optimize specialty drug management. The comprehensive platform combines smart inventory and contract management with on-demand, predictive practice intelligence — simplifying the complexity of buy-and-bill to help independent practices improve drug utilization and economics. AllyIQ integrates
More news about: AllyGPO
Sep 08, 2026, 08:20 ET Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals
More news about: Accro Bioscience (Suzhou) Limited
Sep 08, 2026, 08:17 ET HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
withdrawals, or discontinuations; adverse events were balanced between active arms and placebo, with low rates of injection site reactions and anti-drug antibodies. The first Phase 3 study of HBM9378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is
More news about: Harbour BioMed
Sep 08, 2026, 08:05 ET Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease.
More news about: Alebund Pharmaceuticals
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects,
More news about: Kelun-Biotech
Sep 08, 2026, 08:00 ET Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
agencies, including Breakthrough Therapy Designation and Fast Track Designation from the US Food and Drug Administration; Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products Administration; access granted to the European
More news about: Sanofi